US · ABOS
Acumen Pharmaceuticals, Inc.
Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….
Price · as of 2026-10-09
$2.14
Market cap 161.79M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Acumen Pharmaceuticals, Inc. (ABOS) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
- CEO
- Daniel J. O'Connell
- Employees
- 61
- Beta
- 0.34
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.